Vaxcyte, Inc.
PCVX
Hisse Senetlerindeki Sıralama
#2062
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage,... Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Hisse Fiyatı
$65.37
Piyasa Değeri
$10.03B
Değişim (1 gün)
2.75%
Değişim (1 yıl)
54.21%
Ülke
US
Ticaret Vaxcyte, Inc. (PCVX)
Kategori
Healthcare
Vaxcyte, Inc. (PCVX) için kazanç
Jun 2026 itibarıyla kazanç TTM: $-1.06B
Vaxcyte, Inc. şirketinin en son finansal raporlarına göre, mevcut kazancı $-1.06B'dir. 2023 yılında şirket $-402.27M kazanç elde etti, bu 2022 yılındaki $-223.49M kazanca göre önceki yıla göre azalma. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
Vaxcyte, Inc. için kazanç geçmişi 2017 - 2026
Her yılın sonundaki kazanç
| Yıl | Kazanç | Değiştir |
|---|---|---|
| 2026 (TTM) | $-1.06B | 129.40% |
| 2024 | $-463.93M | 15.33% |
| 2023 | $-402.27M | 80.00% |
| 2022 | $-223.49M | 123.31% |
| 2021 | $-100.08M | 12.17% |
| 2020 | $-89.22M | 77.46% |
| 2019 | $-50.27M | 70.51% |
| 2018 | $-29.49M | 71.05% |
| 2017 | $-17.24M | 0.00% |
Benzer şirketler veya rakipler için kazanç
| Şirket | Kazanç | Kazanç Farkı | Ülke |
|---|---|---|---|
| $5.27B | -595.64% |
US
|
|
| $-3.09B | 190.06% |
US
|
|
| $-4.02B | 277.37% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -283.29% |
NL
|
